m 6 A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2 ‐mediated IGF1R mRNA stabilization
Chuandong Lang,Chi Yin,Kaiyuan Lin,Yue Li,Qing Yang,Zhengquan Wu,Hong Du,Dong Ren,Yuhu Dai,Xinsheng Peng
DOI: https://doi.org/10.1002/ctm2.426
IF: 8.554
2021-06-01
Clinical and Translational Medicine
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Bone metastasis is the leading cause of tumor-related death in prostate cancer (PCa) patients. Long noncoding RNAs (lncRNAs) have been well documented to be involved in the progression of multiple cancers. Nevertheless, the role of lncRNAs in PCa bone metastasis remains largely unclear.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The expression of <i>prostate cancer-associated transcripts</i> was analyzed in published datasets and further verified in clinical samples and cell lines by RT-qPCR and in situ hybridization assays. Colony formation assay, MTT assay, cell cycle analysis, EdU assay, Transwell migration and invasion assays, wound healing assay, and <i>in vivo</i> experiments were carried out to investigate the function of <i>prostate cancer-associated transcript 6</i> (<i>PCAT6</i>) in bone metastasis and tumor growth of PCa. Bioinformatic analysis, RNA pull-down, and RIP assays were conducted to identify the proteins binding to <i>PCAT6</i> and the potential targets of <i>PCAT6</i>. The therapeutic potential of targeting <i>PCAT6</i> by antisense oligonucleotides (ASO) was further explored <i>in vivo</i>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p><i>PCAT6</i> was upregulated in PCa tissues with bone metastasis and increased <i>PCAT6</i> expression predicted poor prognosis in PCa patients. Functional experiments found that <i>PCAT6</i> knockdown significantly inhibited PCa cell invasion, migration, and proliferation <i>in vitro</i>, as well as bone metastasis and tumor growth <i>in vivo</i>. Mechanistically, <i>METTL3</i>-mediated m<sup>6</sup>A modification contributed to <i>PCAT6</i> upregulation in an <i>IGF2BP2</i>-dependent manner. Furthermore, <i>PCAT6</i> upregulated <i>IGF1R</i> expression by enhancing <i>IGF1R</i> mRNA stability through the <i>PCAT6</i>/<i>IGF2BP2</i>/<i>IGF1R</i> RNA-protein three-dimensional complex. Importantly, <i>PCAT6</i> inhibition by ASO <i>in vivo</i> showed therapeutic potential against bone metastasis in PCa. Finally, the clinical correlation of <i>METTL3</i>, <i>IGF2BP2</i>, <i>IGF1R</i>, and <i>PCAT6</i> was further demonstrated in PCa tissues and cells. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Our study uncovers a novel molecular mechanism by which the m<sup>6</sup>A-induced <i>PCAT6</i>/<i>IGF2BP2</i>/<i>IGF1R</i> axis promotes PCa bone metastasis and tumor growth, suggesting that <i>PCAT6</i> may serve as a promising prognostic marker and therapeutic target against bone-metastatic PCa. </p></section>
oncology,medicine, research & experimental